Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside

Research output: Contribution to journalArticle

Abstract

After years of limited progress in the treatment of neuroendocrine neoplasms (NENs), an increasing number of therapeutic targets have recently emerged as potential tools to improve disease outcome. The mammalian target of rapamycin (mTOR) pathway and vascular endothelial growth factor (VEGF) signalling are implicated in the regulation of cell growth, proliferation, neo-angiogenesis and tumour cell spread. Their combined blockade, in a simultaneous or sequential strategy, represents an intriguing biological rationale to overcome the onset of resistance mechanisms. However, is becoming increasingly imperative to find the optimal sequential strategy according to the best toxicity profile, and also to identify predictive biomarkers. We will provide an overview of the pre-clinical and clinical data relating to mTOR pathway/VEGF signalling as a potential targets of treatment in NENs.

Original languageEnglish
Pages (from-to)754-760
Number of pages7
JournalCancer Treatment Reviews
Volume41
Issue number9
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Dual inhibition
  • Hypoxia
  • MTOR pathway
  • Neuroendocrine tumours
  • VEGF signalling

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside'. Together they form a unique fingerprint.

  • Cite this